XR Beta-AM Tablet contains a combination of Amlodipine 5 mg and Metoprolol Succinate 50 mg, formulated for the management of hypertension and angina pectoris. Amlodipine, a long-acting calcium channel blocker, exerts its antihypertensive effect by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, resulting in vasodilation and reduced peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing myocardial oxygen demand. The extended-release formulation ensures sustained plasma concentrations, promoting once-daily dosing and improved patient compliance. XR Beta-AM Tablet is indicated for patients requiring combination therapy to achieve optimal blood pressure control and symptom relief from angina. It is contraindicated in patients with severe bradycardia, cardiogenic shock, or known hypersensitivity to either component. Caution is advised in patients with asthma, diabetes, or peripheral vascular disease. Common adverse effects may include dizziness, fatigue, hypotension, and peripheral edema. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy. XR Beta-AM Tablet should be used under medical supervision, with dosage adjustments based on therapeutic response and tolerability.